Download Full Text (405 KB)
In 2011, advances in research in medical genetics led to the advent of prenatal cell-free DNA (cfDNA) or also known simply as non-invasive prenatal screening or testing (NIPS). This screen consists of analyzation of placental DNA circulating in maternal blood. NIPS has had a major impact on prenatal screening for aneuploidy. Mixed opinions and data exist as to whom this test is most appropriate for. The sensitivity and specificity of this screen in detecting common fetal aneuploidies has been well documented as superior to other screens in high-risk populations, but less so in low-risk obstetric populations. This paper will compare and contrast NIPS to more traditional screening methods such as first trimester maternal serum biochemical assay of human chorionic gonadotropin (hCG) and pregnancy associated plasma protein A (PAPP-A), and second trimester markers which include hCG, unconjugated estriol, inhibin A, and maternal serum alpha-fetoprotein.
Physician Assistant Studies
Master of Physician Assistant Studies (MPAS)
Aneuploidy; Chromosome Disorders -- diagnosis; Genetic Testing; Comparative Study; Fetus -- pathology; Molecular Diagnostic Techniques; Prenatal Diagnosis -- methods
Obstetrics and Gynecology
Watson, Rachel, "Prenatal Screening for Aneuploidy: Should cfDNA Replace Traditional Methods?" (2017). Physician Assistant Scholarly Project Posters. 59.